Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes.
在接受胰島素治療的糖尿病患者中啟動胰高血糖素樣肽-1受體激動劑療法時持續血糖監測的使用。
Diabetes Obes Metab 2024-08-28
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
GLP-1受體激動劑和SGLT2抑制劑在1型糖尿病中的臨床和安全結果:一項真實世界研究。
J Clin Endocrinol Metab 2023-04-02
The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy.
結合GLP-1RA和基礎胰島素治療對於控制不佳的T2D患者使用混合式胰島素治療的療效和安全性。
Medicine (Baltimore) 2023-09-16
Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis.
糖尿病患者中胰高血糖素樣肽-1受體激動劑的臨床療效:一項荟萃分析。
Cell Mol Biol (Noisy-le-grand) 2023-06-22
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.
GLP-1受體激動劑作為額外治療對於第一型糖尿病的胰島素。
Front Pharmacol 2024-01-23
A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
使用胰高血糖素樣肽-1受體激動劑的安全性和有效性評論與荟萃分析。
Medicina (Kaunas) 2024-03-30
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
GLP-1 受體激動劑在管理第2型糖尿病中被低估的情況,儘管其具有良好的效益-安全性檔案。
Expert Opin Drug Saf 2024-05-14
Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy.
葡萄糖樣肽-1 受體激動劑治療開始時基礎和進餐胰島素劑量的滴定。
Cureus 2024-06-10
GLP-1 受體激動劑(GLP-1 RAs)對改善第2型糖尿病的血糖控制非常有效,可以減少胰島素用量。一項研究發現,開始使用GLP-1 RAs 的患者在三個月後,基礎和進餐胰島素用量減少,同時A1c、體重和膽固醇水平也有所改善。這顯示GLP-1 RA 治療對這些方面有積極的影響。
PubMedDOI
Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.
在亞優化治療的2型糖尿病患者中,進行持續葡萄糖監測後A1C變化與GLP-1 RA治療的關聯。
Diabetes Ther 2024-07-15
Use of GLP-1 receptor agonists for the management of type 1 diabetes: A pediatric perspective.
GLP-1 受體激動劑在 1 型糖尿病管理中的應用:兒科觀點。
Horm Res Paediatr 2024-09-02